![]() |
|
|
Vol. 298, Issue 3, 1101-1107, September 2001
Departments of Psychiatry (A.J.M., A.D., M.E.P., S.V.-L., I.L.) and
Pharmacology (I.L.), University of Pennsylvania, Philadelphia,
Pennsylvania; and Center for Neurobiology and Behavior, Columbia
University, New York, New York (R.H.)
The development of serotonin receptor knockout mice has provided an
opportunity to study antidepressant drug effects in animals with
targeted genetic deletion of receptors involved in antidepressant responses. In the current study, the effects of two types of
antidepressant drugs, the selective serotonin reuptake inhibitors
fluoxetine and paroxetine and the selective norepinephrine reuptake
inhibitor desipramine, were examined in 5-hydroxytryptamine
(5-HT)1A and 5-HT1B receptor mutant mice using
the tail suspension test (TST). Under baseline conditions, the
immobility of 5-HT1A receptor mutant mice, but not
5-HT1B receptor mutant mice, was significantly lower than
that of wild-type mice. The decreased baseline immobility in
5-HT1A receptor mutant mice was reversed by pretreatment
with
-methyl-para-tyrosine, but not by
para-chlorophenylalanine, suggesting mediation by
enhanced catecholamine function. In wild-type mice, fluoxetine
(10.0-20.0 mg/kg i.p.) and desipramine (5.0-20.0 mg/kg i.p.) both
significantly decreased immobility in the TST. In 5-HT1A receptor mutant mice, desipramine (20.0 mg/kg i.p.) significantly decreased immobility, whereas fluoxetine (20.0 mg/kg i.p.) and paroxetine (20.0 mg/kg i.p.) had no effect. The immobility of 5-HT1B receptor mutant mice was decreased similarly by
desipramine (5.0-20.0 mg/kg i.p.). However, the effect of low doses of
fluoxetine were significantly augmented in the 5-HT1B
receptor mutant mice (2.5-20.0 mg/kg i.p.) compared with wild-type
mice. Administration of selective 5-HT receptor antagonists in
wild-type mice partially reproduced the phenotypes of the mutant mice.
These results suggest that 5-HT1A and 5-HT1B
receptors have different roles in the modulation of the response to
antidepressant drugs in the TST.
This article has been cited by other articles:
![]() |
T. Y.C. Pang, X. Du, M. S. Zajac, M. L. Howard, and A. J. Hannan Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease Hum. Mol. Genet., February 15, 2009; 18(4): 753 - 766. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Warner-Schmidt, M. Flajolet, A. Maller, E. Y. Chen, H. Qi, P. Svenningsson, and P. Greengard Role of p11 in Cellular and Behavioral Effects of 5-HT4 Receptor Stimulation J. Neurosci., February 11, 2009; 29(6): 1937 - 1946. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Svenningsson, E. T. Tzavara, H. Qi, R. Carruthers, J. M. Witkin, G. G. Nomikos, and P. Greengard Biochemical and Behavioral Evidence for Antidepressant-Like Effects of 5-HT6 Receptor Stimulation J. Neurosci., April 11, 2007; 27(15): 4201 - 4209. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Page, J. F. Cryan, A. Sullivan, A. Dalvi, B. Saucy, D. R. Manning, and I. Lucki Behavioral and Neurochemical Effects of 5-{4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl}-benzofuran-2-carboxamide (EMD 68843): A Combined Selective Inhibitor of Serotonin Reuptake and 5-Hydroxytryptamine1A Receptor Partial Agonist J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1220 - 1227. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Knobelman, R. Hen, and I. Lucki Genetic Regulation of Extracellular Serotonin by 5-Hydroxytryptamine1A and 5-Hydroxytryptamine1B Autoreceptors in Different Brain Regions of the Mouse J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1083 - 1091. [Abstract] [Full Text] [PDF] |
||||